EMBRACE Study: Enduring Migraine Benefit From Responsive Artery Coil Embolization
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-60
SponsorCortex Neurovascular
About this trial
This single-site, open-label pilot study evaluates the safety, feasibility, and potential durability of the TEMMA procedure (Targeted Embolization for Migraine Management), an endovascular treatment strategy targeting meningeal arterial contributors to migraine. Adults aged 18-60 with refractory migraine despite prior preventive therapies are eligible. The study assesses migraine outcomes over 12 months using patient-reported headache frequency, pain intensity, acute medication use, migraine-related disability (MIDAS), and quality-of-life measures (MSQ v2.1).
Eligibility criteria
Qualifiers
Age 18-60 years
Diagnosis of migraine (with or without aura)
Failure of ≥2 preventive medication classes
Ability to complete electronic headache diary and surveys
Disqualifiers
Secondary headache disorders
Prior MMA embolization
Contraindication to angiography or embolization
Pregnancy
Trial design
Treatments tested in this trial
- TEMMA Endovascular Treatment
Treatment groups
25 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov